CA2759481A1 - Tissue kallikrein for the treatment of schizophrenia and bipolar disorder - Google Patents

Tissue kallikrein for the treatment of schizophrenia and bipolar disorder Download PDF

Info

Publication number
CA2759481A1
CA2759481A1 CA2759481A CA2759481A CA2759481A1 CA 2759481 A1 CA2759481 A1 CA 2759481A1 CA 2759481 A CA2759481 A CA 2759481A CA 2759481 A CA2759481 A CA 2759481A CA 2759481 A1 CA2759481 A1 CA 2759481A1
Authority
CA
Canada
Prior art keywords
per day
schizophrenia
variant
klk1
psychiatric disorder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2759481A
Other languages
English (en)
French (fr)
Inventor
Matthew Charles
Mark Williams
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanomune Inc
Original Assignee
Sanomune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanomune Inc filed Critical Sanomune Inc
Publication of CA2759481A1 publication Critical patent/CA2759481A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4853—Kallikrein (3.4.21.34 or 3.4.21.35)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
CA2759481A 2009-04-21 2010-04-21 Tissue kallikrein for the treatment of schizophrenia and bipolar disorder Abandoned CA2759481A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17118909P 2009-04-21 2009-04-21
US61/171,189 2009-04-21
PCT/CA2010/000561 WO2010121358A1 (en) 2009-04-21 2010-04-21 Tissue kallikrein for the treatment of schizophrenia and bipolar disorder

Publications (1)

Publication Number Publication Date
CA2759481A1 true CA2759481A1 (en) 2010-10-28

Family

ID=43010629

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2759481A Abandoned CA2759481A1 (en) 2009-04-21 2010-04-21 Tissue kallikrein for the treatment of schizophrenia and bipolar disorder

Country Status (6)

Country Link
US (1) US20120201804A1 (OSRAM)
EP (1) EP2421553A4 (OSRAM)
JP (1) JP2012524112A (OSRAM)
CN (1) CN102458453A (OSRAM)
CA (1) CA2759481A1 (OSRAM)
WO (1) WO2010121358A1 (OSRAM)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2693921A1 (en) 2007-07-20 2009-01-29 Genesys Venture Inc. Tissue kallikrein for the treatment of diseases associated with amyloid protein
WO2013173923A1 (en) 2012-05-25 2013-11-28 Diamedica, Inc. Formulations of human tissue kallikrein-1 for parenteral delivery and related methods
HUE032613T2 (en) 2012-06-04 2017-10-30 Diamedica Therapeutics Inc Human tissue kallikrein 1 is glycosylated isoforms
US11174317B2 (en) 2015-06-04 2021-11-16 National Center Of Neurology And Psychiatry Therapeutic agent for mental illness comprising IL-6 inhibitor as active ingredient
US11337932B2 (en) 2016-12-20 2022-05-24 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine and polysiloxane or polyisobutylene
CN110087640A (zh) 2016-12-20 2019-08-02 罗曼治疗系统股份公司 包含阿塞那平的透皮治疗系统
WO2018165551A1 (en) 2017-03-09 2018-09-13 Diamedica Inc. Dosage forms of tissue kallikrein 1
JP2020525545A (ja) 2017-06-26 2020-08-27 エルテーエス ローマン テラピー−ジステーメ アーゲー アセナピンおよびシリコーンアクリルハイブリッドポリマーを含有する経皮治療システム
US12329862B2 (en) 2018-06-20 2025-06-17 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine
CN112704672A (zh) 2018-06-20 2021-04-27 罗曼治疗系统股份公司 含有阿塞那平的透皮治疗系统
CN109091667B (zh) * 2018-09-18 2020-05-05 广东天普生化医药股份有限公司 人尿激肽原酶在制备治疗偏头痛药物中的用途及其组合物
CN116549619A (zh) * 2022-01-28 2023-08-08 江苏众红生物工程创药研究院有限公司 激肽原酶及其衍生物在治疗vci、psci或csvd中的应用
CN116549599A (zh) * 2022-01-30 2023-08-08 江苏众红生物工程创药研究院有限公司 激肽及其衍生物在治疗vci、psci或csvd中的应用
CN116554267A (zh) * 2022-01-30 2023-08-08 江苏众红生物工程创药研究院有限公司 聚乙二醇修饰的激肽或其变体和药物应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2693921A1 (en) * 2007-07-20 2009-01-29 Genesys Venture Inc. Tissue kallikrein for the treatment of diseases associated with amyloid protein
WO2010009557A1 (en) * 2008-07-25 2010-01-28 Sanomune Inc. Tissue kallikrein for the treatment of parkinson's disease

Also Published As

Publication number Publication date
WO2010121358A1 (en) 2010-10-28
EP2421553A4 (en) 2012-11-28
JP2012524112A (ja) 2012-10-11
CN102458453A (zh) 2012-05-16
EP2421553A1 (en) 2012-02-29
US20120201804A1 (en) 2012-08-09

Similar Documents

Publication Publication Date Title
US20120201804A1 (en) Tissue kallikrein for the treatment of schizophrenia and bipolar disorder
Oudega Molecular and cellular mechanisms underlying the role of blood vessels in spinal cord injury and repair
Beroun et al. MMPs in learning and memory and neuropsychiatric disorders
Jain Neuroprotection in traumatic brain injury
Gao et al. Damage mechanism and therapy progress of the blood-brain barrier after ischemic stroke
US8501695B2 (en) Tissue kallikrein for the treatment of diseases associated with amyloid protein
US11572396B2 (en) Therapeutic use of bone morphogenetic proteins
US20110150781A1 (en) Tissue kallikrein for the treatment of parkinson's disease
V. Borlongan et al. Breaking the barrier in stroke: What should we know? A mini-review
Zhou et al. Crosstalk between soluble PDGF‐BB and PDGFRβ promotes astrocytic activation and synaptic recovery in the hippocampus after subarachnoid hemorrhage
Gao et al. Enhancement of neural regeneration as a therapeutic strategy for Alzheimer's disease
Gong et al. Research developments in the neurovascular unit and the blood‑brain barrier
US20120225051A1 (en) Tissue kallikrein for the treatment of huntington's disease
CN109715194B (zh) 用于治疗神经障碍的颤蛋白组合物
Nury et al. Roles and potential therapeutic targets of the ubiquitin proteasome system in muscle wasting
JP2014505010A (ja) 脳損傷治療用ｓｔｅｐ誘導ペプチド
CN120379657A (zh) 用于治疗瘦素抵抗性肥胖的选择性下丘脑可渗透的hdac6抑制剂
Oliveira Miranda Mesenchymal stem cells for lysosomal storage and polyglutamine disorders: possible shared mechanisms
Loan et al. Treatment options in motor neuron disease: Amyotrophic lateral sclerosis and spinal muscular atrophy
Kobayashi et al. Revaluation of Thyrotropin-Releasing Hormone and Its Mimetics as Candidates for Treating a Wide Range of Neurological and Psychiatric Disorders
Cruz-Torres Modifications to TRPM2 channel activity following global cerebral ischemia
EA045597B1 (ru) Композиции рилина для лечения неврологических расстройств
Liu Src Family Kinases in Intracerebral Hemorrhage
GB2542776A (en) Treatment of neurological conditions by activation of stem cells

Legal Events

Date Code Title Description
FZDE Dead

Effective date: 20150422